Epuris · DIN 02396971 · 10 mg · capsule
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Epuris · DIN 02396971
Manufacturer: Cipher Pharmaceuticals Inc.; listing date 2014-02-27
Health Canada: Marketed since 2013-05-07 · brand EPURIS · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 10 MG · company Cipher pharmaceuticals inc · schedule Prescription
Epuris: Formulary list price $1.54 per unit (the source does not state the unit; exact figure $1.5441). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02396971)
Source record
DIN 02396971: Epuris
Raw flags: sec3=Y
Item: 843600095; group id 864; item number 2087; lccId None; manufacturer id CIP
Source form: Cap; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $1.5441; ministry $1.5441
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02396971
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88198
Therapeutic Notes (formulary)
Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Shortage status: not checked (no credentials)